This study is being done to determine if lidocaine, administered during surgery and for 24 hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation and 30 day mortality after surgery. Participants undergoing cardiac surgery will be randomized to receive either lidocaine or placebo.

Brief Title

Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery

Official Title

The Effect of Perioperative Intravenous Lidocaine on Postoperative Outcomes After Cardiac Surgery

Brief Summary

This study is being done to determine if lidocaine, administered during surgery and for 24<br /> hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation<br /> and 30 day mortality after surgery. Participants undergoing cardiac surgery will be<br /> randomized to receive either lidocaine or placebo.

Detailed Description

Subjects undergoing cardiac surgery are randomized into one of two groups.

- Group 1: Intravenous Lidocaine Group

- Group 2: Intravenous placebo Group

Either Lidocaine or placebo is administered throughout surgery and 24 hours after surgery.

Patients in both groups will undergo quality of life assessments and functional recovery
assessments post-surgery.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.